09:40 - 10:00

Day 2 – February 2, 2023


Monitoring therapeutic response in B-cell lymphoblastic Leukemia (B-ALL) using flow cytometry is well-established. CD19 is an ideal gating B-cell marker and most of the gating strategies depend on it. Based on immunotherapy targeting CD19, new approaches are developed. This presentation shows alternative gating strategies after immunotherapy of minimal residual disease (MRD) determination in B-ALL and the pitfalls for identification B-cell precursor cells during immunotherapies and relapse.

The speakers